Technical Specifications for Submitting Clinical Trial Data Sets for Response Assessments for Treatments of Acute Leukemias
Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers
Quality Management System Information for Certain Premarket Submission Reviews
Menstrual Products – Performance Testing and Labeling Recommendations
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies
New FDA Draft Guidance: Elevating Safety, Transparency & Testing for Menstrual Products
Introduction In October 2025, the FDA published a draft guidance titled Menstrual Products – Performance Testing and Labeling Recommendations (Draft Guidance for Industry and FDA Staff). U.S. Food and Drug AdministrationThis guidance provides non-binding recommendations for manufacturers of menstrual products (tampons, pads, menstrual cups) regarding performance testing, specification, materials/disclosure, and labeling. U.S. Food and Drug […]
Research Report — Contaminated Cough Syrups in India (Oct 2025): Scope, Data, Regulatory Response, and Public-Health Implications
Prepared for: Shudarsana Company / Regulatory & Safety StakeholdersDate: 15 October 2025 (content current as of 15 Oct 2025)Sources: FDA, Reuters, WHO-related reporting, RAPS, Chemistry World, Reuters investigative archives, peer-reviewed summaries. Key sources cited inline. Executive summary (key facts & numbers) Background: DEG/EG contamination — why it kills Diethylene glycol (DEG) and ethylene glycol (EG) […]
A Deep Dive into the FDA Approval of NDA 215244 (s000): What We Know, What It Means, and What Comes Next
Introduction The issuance of label 215244s000 marks the formal U.S. FDA approval of a new therapeutic agent (or new indication) under NDA 215,244. While publicly available summaries are scarce, the full prescribing label document offers a wealth of technical information that can be unpacked to understand the drug’s mechanism, safety/efficacy profile, clinical trial evidence, potential […]
When Sleep Therapy Devices Go Wrong: Philips DreamStation Ventilator Recall Explained
Sleep apnea affects millions. For many, devices like CPAPs or BiPAPs are lifelines — nightly helpers that keep airways open, ensure proper oxygenation, and protect against serious health risks. So when devices meant to heal can potentially misbehave, it’s a serious matter. Recently, Philips Respironics initiated a recall for certain DreamStation Auto CPAP / Auto […]